Skip to content

    Micromedex Training Center

    IMG-Micromedex-Web-Lead-015-1104x552

    OVERVIEW

    Micromedex® Compendia Resources

    Through the process established by the Centers for Medicare and Medicaid Services (CMS), Micromedex® DRUGDEX® is recognized by CMS as a compendium for the determination of payment for medically-accepted off-label uses for anti-cancer regimens. Effective January 1, 2010, new requirements were implemented that include a provision for providing transparency of processes used to evaluate therapies and to identify potential conflicts of interest. Specifically, publishers of compendia must now make the following information available via their public websites:

    • Criteria used to evaluate the request (therapy)
    • Disclosure of evidence considered
    • Meeting minutes and records of votes for disposition of the request (therapy)
    • Names of individuals who have substantively participated in the development of the compendia recommendations and disclosure of any potential conflicts of interest

    To meet these requirements, documents detailing this information for each drug/off-label use pair published on or after January 1, 2010 are posted below. Information is organized by drug name, with the document title indicating the off-label use. Further transparency regarding Micromedex Off-Label processes can be found in the Micromedex Compendia Uses Policy.

    Micromedex® Compendia Policy

    This document outlines the policy and procedures employed by Micromedex® Editorial teams to identify clinically relevant off-label uses for FDA-approved medications and develop evidence-based content for inclusion in Micromedex content sets to support the designation of DRUGDEX® as a named compendium for the CMS. 3 pages

    Micromedex® Off-label Request Process

    This document outlines the process by which external parties may submit a request for a new off-label use to be evaluated for inclusion in Micromedex DRUGDEX®. Any consideration will be done independently by Micromedex editorial staff following existing policies to maintain objectivity and editorial independence. 2 pages

    Get to know our capabilities

    Explore the Micromedex capabilities and features that provide comprehensive clinical decision support for clinicians at the point of care.

    Antithymocyte globulin equine

    Asparaginase Escherichia Coli

    Dexmethylphenidate

    Ketamine hydrochloride

    Melphalan Hydrochloride

    Methylphenidate Hydrochloride

    Peginterferon alfa-2b